Actively Recruiting
Phase 1 Randomized, Double-Blind Study of Tirzepatides Effect on Gastric Emptying in Adults with Type 1 Diabetes and Overweight or Obesity
Led by Eli Lilly and Company · Updated on 2026-09-23
18
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how the drug tirzepatide affects stomach emptying in adults with Type 1 Diabetes Mellitus T1DM who are also overweight or obese. This early phase 1 trial aims to understand the bodys response to tirzepatide compared to a placebo, focusing on how it influences the digestion process. Participants will receive either a single dose of tirzepatide injected under the skin along with oral acetaminophen or a placebo injection with oral acetaminophen. The study uses a randomized, double-blind design where neither the participants nor the investigators know which treatment is given. The study lasts about 8 weeks, including screening and follow-up. During the study, participants will undergo blood tests to track levels of acetaminophen and tirzepatide over time to measure how quickly the stomach empties. Researchers will monitor drug concentration at multiple time points up to 36 hours after dosing for acetaminophen and up to 29 days for tirzepatide. Safety and tolerability will also be assessed throughout the study.
CONDITIONS
Brief Title
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here